HC Wainwright Has Negative Forecast for Rezolute Q2 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Equities researchers at HC Wainwright dropped their Q2 2027 earnings estimates for shares of Rezolute in a note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.18) for the quarter, down from their previous forecast of ($0.14). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Rezolute’s Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.51) EPS, FY2029 earnings at ($0.27) EPS and FY2030 earnings at $1.30 EPS.

A number of other equities analysts have also recently weighed in on the stock. Zacks Research cut shares of Rezolute from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. Lake Street Capital boosted their price target on shares of Rezolute from $9.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. Cantor Fitzgerald upgraded shares of Rezolute from a “neutral” rating to an “overweight” rating in a research report on Monday, October 5th. Citigroup reaffirmed a “market outperform” rating on shares of Rezolute in a research note on Thursday, October 15th. Finally, Craig Hallum raised Rezolute from a “hold” rating to a “buy” rating and raised their price objective for the stock from $4.00 to $7.00 in a research note on Tuesday, September 29th. Twelve research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Rezolute presently has a consensus rating of “Moderate Buy” and an average price target of $11.22.

Rezolute Stock Down 0.3%

Shares of NASDAQ:RZLT opened at $3.87 on Tuesday. The company has a 50 day moving average price of $4.12 and a two-hundred day moving average price of $3.91. Rezolute has a 52 week low of $1.07 and a 52 week high of $11.46.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.

Institutional Trading of Rezolute

Hedge funds have recently bought and sold shares of the stock. Auxano Advisors LLC bought a new position in Rezolute in the second quarter valued at approximately $52,000. Sequoia Financial Advisors LLC bought a new stake in Rezolute in the 2nd quarter valued at $75,000. WINTON GROUP Ltd bought a new stake in Rezolute in the 2nd quarter valued at $88,000. Y Intercept Hong Kong Ltd bought a new stake in Rezolute in the 1st quarter valued at $90,000. Finally, Hsbc Holdings PLC boosted its stake in Rezolute by 189.4% in the 1st quarter. Hsbc Holdings PLC now owns 36,939 shares of the company’s stock worth $113,000 after purchasing an additional 24,177 shares during the period. 82.97% of the stock is currently owned by institutional investors and hedge funds.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company’s lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.